rs199983343
Variant summary
Our verdict is Likely benign. The variant received -1 ACMG points: 3P and 4B. PM2PP2BP4_Strong
The NM_001278716.2(FBXL4):c.131C>A(p.Thr44Asn) variant causes a missense change. The variant allele was found at a frequency of 0.0000595 in 1,614,066 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. T44S) has been classified as Uncertain significance.
Frequency
Consequence
NM_001278716.2 missense
Scores
Clinical Significance
Conservation
Publications
- Leigh syndromeInheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
- mitochondrial DNA depletion syndrome 13Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -1 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000118 AC: 18AN: 152200Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.000135 AC: 34AN: 251404 AF XY: 0.000125 show subpopulations
GnomAD4 exome AF: 0.0000534 AC: 78AN: 1461866Hom.: 0 Cov.: 31 AF XY: 0.0000454 AC XY: 33AN XY: 727236 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000118 AC: 18AN: 152200Hom.: 0 Cov.: 32 AF XY: 0.0000941 AC XY: 7AN XY: 74374 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Mitochondrial DNA depletion syndrome 13 Uncertain:2
This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. -
The NM_012160.4:c.131C>A (NP_036292.2:p.Thr44Asn) [GRCH38: NC_000006.12:g.98926858G>T] variant in FBXL4 gene is interpretated to be a Uncertain Significance - Conflicting Evidence based on ACMG guidelines (PMID: 25741868). This variant meets one or more of the following evidence codes reported in the ACMG-guideline. PM2:This variant is absent in key population databases. BP4:Computational evidence/predictors indicate no impact on the FBXL4 structure, function, or protein-protein interaction. Based on this evidence code ClinGen Pathogenicity Calculator (PMID:28081714) suggested that the variant is Uncertain Significance - Conflicting Evidence. -
not provided Uncertain:1
This sequence change replaces threonine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 44 of the FBXL4 protein (p.Thr44Asn). This variant is present in population databases (rs199983343, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with FBXL4-related conditions. ClinVar contains an entry for this variant (Variation ID: 437542). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt FBXL4 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at